Showing 4371-4380 of 19393 results for "".
Acute Decompensated Heart Failure:the UNLOAD Trial
https://reachmd.com/programs/clinicians-roundtable/acute-decompensated-heart-failurethe-unload-trial/137/Dr. Anderson reviews the UNLOAD Trial and its findings.The Proliferation of Food Allegies
https://reachmd.com/programs/clinicians-roundtable/the-proliferation-of-food-allegies/74/Dr. Clifford Bassett, Allergist and Assistant Clinical Professor of Medicine and Otolaryngology at Long Island College Hospital in New York speaks about the "why" behind food allergies and cultural factors affecting the field.Treating Skin Manifestations of Connective Tissue Diseases
https://reachmd.com/programs/clinicians-roundtable/treating-skin-manifestations-of-connective-tissue-diseases/32387/Explore how targeted therapies can improve dermatological symptoms of autoimmune diseases.Cost Considerations for Colorectal Cancer Screening: Examining the Data
https://reachmd.com/programs/clinicians-roundtable/cost-considerations-for-colorectal-cancer-screening-examining-the-data/33054/A recent study explored three emerging colorectal cancer (CRC) screening tests—mt-sRNA, multitarget stool DNA 2.0, and cell-free DNA—in terms of their cost-effectiveness, comparing them to traditional methods such as colonoscopy and fecal immunochemical testing. Learn which methods offer the best baAdvancing HER2-Targeted Therapy in GI Cancers
https://reachmd.com/programs/project-oncology/her2-targeted-therapy-gi-cancer/49170/The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins us to share insights on how recent FDA approvals and novel agents are transforming outcomePromising Therapies on the Atopic Dermatitis Horizon
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37178/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, previews important potential developments in the atopic dermatitis pipelineTailoring Pediatric Acne Care: A Look at Topical and Systemic Options
https://reachmd.com/programs/clinicians-roundtable/tailoring-pediatric-acne-care-a-look-at-topical-and-systemic-options/30055/Discover insights on how to effectively tailor pediatric acne management as improved treatment options become available.T-Cell Characteristics: Key Players in Bispecific Antibody Treatment Success
https://reachmd.com/programs/project-oncology/t-cell-characteristics-key-players-in-bispecific-antibody-treatment-success/26580/T-cell bispecific antibodies (BsAbs) have emerged as a promising immunotherapy approach in cancer treatment.Optimizing C3G Management: The Power of Lifestyle Changes and Supportive Care
https://reachmd.com/programs/frontlines-c3g/optimizing-c3g-management-the-power-of-lifestyle-changes-and-supportive-care/35489/For patients with C3 glomerulopathy (C3G), supportive care is a critical yet often underemphasized component of disease management. Join Dr. Richard Lafayette as he outlines key strategies to reduce risks, improve quality of life, and empower patients to engage actively in their long-term care. Dr.Outcomes for PDR Patients LTFU for at Least 1 Year
https://reachmd.com/programs/new-retina-radio/outcomes-for-pdr-patients-ltfu-for-at-least-1-year/48969/How did patients with PDR fare after being lost to follow-up for at least 1 year and then returning to the clinic? Kyle Kovacs, MD, is joined by Matt Starr, MD, and Nita Valikodath, MD, MS, to explore a recent paper that leveraged the power the IRIS Registry to assess real-world outcomes for this im